GPS Wealth Strategies Group’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-17
Closed -$343 – 1470
2025
Q3
$343 Hold
17
– – ﹤0.01% 1549
2025
Q2
$285 Buy
17
+12
+240% +$194 ﹤0.01% 1527
2025
Q1
$77 Buy
+5
New +$89 ﹤0.01% 1469
2024
Q1
– Sell
-300
Closed -$3.13K – 1299
2023
Q4
$3.13K Hold
300
– – ﹤0.01% 1062
2023
Q3
$3.06K Hold
300
– – ﹤0.01% 1065
2023
Q2
$2.26K Sell
300
-280
-48% -$2.27K ﹤0.01% 1102
2023
Q1
$5.13K Buy
+580
New +$5.74K ﹤0.01% 971
2022
Q4
– Sell
-580
Closed -$5K – 976
2022
Q3
$5K Hold
580
– – ﹤0.01% 905
2022
Q2
$4K Hold
580
– – ﹤0.01% 949
2022
Q1
$5K Hold
580
– – ﹤0.01% 862
2021
Q4
$5K Hold
580
– – ﹤0.01% 871
2021
Q3
$6K Sell
580
-175
-23% -$1.64K ﹤0.01% 813
2021
Q2
$7K Buy
755
+175
+30% +$1.85K ﹤0.01% 813
2021
Q1
$6K Buy
+580
New +$6.65K ﹤0.01% 758

Other funds holding TEVA

GPS Wealth Strategies Group's TEVA Position: Q4 2025 in Review

GPS Wealth Strategies Group sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q4 2025, closing a stake of 17 shares — an estimated $343 sold.

GPS Wealth Strategies Group first reported a position in TEVA in Q1 2021 and held it in 14 quarters. The position peaked at $7K in Q2 2021. 632 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • GPS Wealth Strategies Group reported no remaining Teva Pharmaceutical Industries Limited position as of Q4 2025 after selling out during the quarter.
  • GPS Wealth Strategies Group sold 17 Teva Pharmaceutical Industries Limited shares in Q4 2025, an estimated $343.
  • GPS Wealth Strategies Group first reported a position in Teva Pharmaceutical Industries Limited in Q1 2021 and held it in 14 quarters.
  • GPS Wealth Strategies Group's Teva Pharmaceutical Industries Limited position peaked at $7K in Q2 2021.
  • 632 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q4 2025.

Based on GPS Wealth Strategies Group's 13F filing for Q4 2025, filed 6 Feb 2026.